BR112022019369A2 - Lipídios e composições de nanopartículas dos mesmos - Google Patents

Lipídios e composições de nanopartículas dos mesmos

Info

Publication number
BR112022019369A2
BR112022019369A2 BR112022019369A BR112022019369A BR112022019369A2 BR 112022019369 A2 BR112022019369 A2 BR 112022019369A2 BR 112022019369 A BR112022019369 A BR 112022019369A BR 112022019369 A BR112022019369 A BR 112022019369A BR 112022019369 A2 BR112022019369 A2 BR 112022019369A2
Authority
BR
Brazil
Prior art keywords
lipids
nanoparticle compositions
compositions
capsid
formula
Prior art date
Application number
BR112022019369A
Other languages
English (en)
Portuguese (pt)
Inventor
G Stanton Matthew
Nolting Birte
Original Assignee
Generation Bio Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Generation Bio Co filed Critical Generation Bio Co
Publication of BR112022019369A2 publication Critical patent/BR112022019369A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BR112022019369A 2020-03-27 2021-03-26 Lipídios e composições de nanopartículas dos mesmos BR112022019369A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063000990P 2020-03-27 2020-03-27
PCT/US2021/024413 WO2021195529A2 (en) 2020-03-27 2021-03-26 Novel lipids and nanoparticle compositions thereof

Publications (1)

Publication Number Publication Date
BR112022019369A2 true BR112022019369A2 (pt) 2022-12-13

Family

ID=77890624

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022019369A BR112022019369A2 (pt) 2020-03-27 2021-03-26 Lipídios e composições de nanopartículas dos mesmos

Country Status (11)

Country Link
US (3) US12534435B2 (cg-RX-API-DMAC7.html)
EP (1) EP4125821A4 (cg-RX-API-DMAC7.html)
JP (2) JP7746280B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220160647A (cg-RX-API-DMAC7.html)
CN (1) CN115916163A (cg-RX-API-DMAC7.html)
AU (1) AU2021241696B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022019369A2 (cg-RX-API-DMAC7.html)
CA (1) CA3173126A1 (cg-RX-API-DMAC7.html)
IL (1) IL296763B2 (cg-RX-API-DMAC7.html)
MX (1) MX2022011988A (cg-RX-API-DMAC7.html)
WO (1) WO2021195529A2 (cg-RX-API-DMAC7.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3864163T3 (da) 2018-10-09 2024-05-06 Univ British Columbia Sammensætninger og systemer omfattende transfektionskompetente vesikler fri for organiske opløsningsmidler og rengøringsmidler og fremgangsmåder forbundet dermed
US12534435B2 (en) * 2020-03-27 2026-01-27 Generation Bio Co. Lipids and nanoparticle compositions thereof
AU2021307952A1 (en) * 2020-07-17 2023-03-02 Generation Bio Co. Methods for encapsulating polynucleotides into reduced sizes of Lipid nanoparticles and novel formulation thereof
CN117098541A (zh) 2020-11-25 2023-11-21 阿卡格拉医药公司 用于递送核酸的脂质纳米粒及相关使用方法
CN118251212A (zh) * 2021-09-30 2024-06-25 日油株式会社 用于将核酸递送至淋巴管内皮细胞的脂质纳米颗粒
WO2023121964A1 (en) * 2021-12-20 2023-06-29 Beam Therapeutics Inc. Nanomaterials comprising disulfides
JPWO2023190164A1 (cg-RX-API-DMAC7.html) * 2022-03-28 2023-10-05
CA3247022A1 (en) 2022-03-28 2025-07-08 National University Corporation Chiba University METHOD FOR PRODUCING LIPID NANOPARTICLES ENCAPSULATED IN A NUCLEIC ACID, METHOD FOR PRODUCING A PHARMACEUTICAL COMPOSITION CONTAINING SAID LIPID NANOPARTICLES, AND METHOD FOR INTRODUCING NUCLEIC ACID INTO A CELL OR A TARGET CELL
WO2023190175A1 (ja) 2022-03-28 2023-10-05 日油株式会社 末梢血単核細胞へ核酸を送達するための脂質ナノ粒子およびこれを用いて末梢血単核細胞へ核酸を送達する方法
JPWO2023190176A1 (cg-RX-API-DMAC7.html) 2022-03-28 2023-10-05
WO2023230587A2 (en) 2022-05-25 2023-11-30 Akagera Medicines, Inc. Lipid nanoparticles for delivery of nucleic acids and methods of use thereof
KR20250038709A (ko) 2022-07-15 2025-03-19 니치유 가부시키가이샤 지질 나노입자 및 이의 제조 방법, 핵산-캡슐화 지질 나노입자 및 이의 제조 방법, 및 핵산-캡슐화 지질 나노입자를 사용하여 생체에서 획득 면역을 유도하는 방법
KR20250037535A (ko) 2022-07-15 2025-03-17 니치유 가부시키가이샤 핵산-로딩된 지질 나노입자의 동결건조 조성물
WO2024192528A1 (en) * 2023-03-22 2024-09-26 Nanovation Therapeutics Inc. Ionizable anionic lipids
WO2024203660A1 (ja) 2023-03-29 2024-10-03 国立大学法人東北大学 核酸内封脂質ナノ粒子の製造方法
CN116082184B (zh) * 2023-04-12 2023-06-30 山东大学 基于环己二胺的可电离脂质、脂质纳米颗粒及其制备方法与应用
EP4719352A1 (en) 2023-05-31 2026-04-08 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025043146A2 (en) * 2023-08-24 2025-02-27 Molecular Axiom Inc. Lipid nanoparticle compositions and methods of using same
CN121909024A (zh) 2023-09-22 2026-04-21 国立大学法人东北大学 包封有核酸的配体修饰脂质纳米颗粒的制造方法
US20260234104A1 (en) * 2023-12-15 2026-08-13 Xiamen Sinopeg Biotech Co., Ltd. Degradable cationic lipid containing a disulfide bond and applications thereof
WO2025150516A1 (ja) 2024-01-12 2025-07-17 日油株式会社 核酸内封脂質ナノ粒子を含む凍結組成物
CN117964577B (zh) * 2024-03-29 2024-06-21 天津全和诚生物技术有限公司 阳离子脂质化合物、其制备方法、包含其的组合物及应用
WO2026003582A2 (en) 2024-06-27 2026-01-02 Axelyf ehf. Lipids and lipid nanoparticles
WO2026070952A1 (ja) * 2024-09-27 2026-04-02 日油株式会社 ジスルフィド結合を有する化合物およびその製造方法

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5928906A (en) 1996-05-09 1999-07-27 Sequenom, Inc. Process for direct sequencing during template amplification
CA2289702C (en) 1997-05-14 2008-02-19 Inex Pharmaceuticals Corp. High efficiency encapsulation of charged therapeutic agents in lipid vesicles
US6320017B1 (en) 1997-12-23 2001-11-20 Inex Pharmaceuticals Corp. Polyamide oligomers
AU6814901A (en) 2000-06-01 2001-12-11 Univ North Carolina Methods and compounds for controlled release of recombinant parvovirus vectors
WO2002087541A1 (en) 2001-04-30 2002-11-07 Protiva Biotherapeutics Inc. Lipid-based formulations for gene transfer
EP1519714B1 (en) 2002-06-28 2010-10-20 Protiva Biotherapeutics Inc. Method and apparatus for producing liposomes
CN1882693B (zh) 2003-09-15 2012-08-15 普洛体维生物治疗公司 聚乙二醇修饰的脂质化合物及其应用
US7404969B2 (en) 2005-02-14 2008-07-29 Sirna Therapeutics, Inc. Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
JP5639338B2 (ja) 2005-07-27 2014-12-10 プロチバ バイオセラピューティクス インコーポレイティッド リポソームの製造システムおよび製造方法
WO2008103276A2 (en) 2007-02-16 2008-08-28 Merck & Co., Inc. Compositions and methods for potentiated activity of biologicaly active molecules
EP3100718B1 (en) 2008-01-02 2019-11-27 Arbutus Biopharma Corporation Improved compositions and methods for the delivery of nucleic acids
EP2279254B1 (en) 2008-04-15 2017-07-05 Protiva Biotherapeutics Inc. Novel lipid formulations for nucleic acid delivery
EP2310440A4 (en) 2008-07-10 2013-06-05 Serina Therapeutics Inc POLYOXAZOLINES WITH INTERNAL END GROUPS, POLYOXAZOLINES MANUFACTURED FROM PROTECTED INITIAL GROUPS AND CORRESPONDING COMPOUNDS
EP3391877A1 (en) 2010-04-08 2018-10-24 The Trustees of Princeton University Preparation of lipid nanoparticles
WO2011139911A2 (en) 2010-04-29 2011-11-10 Isis Pharmaceuticals, Inc. Lipid formulated single stranded rna
US9006417B2 (en) 2010-06-30 2015-04-14 Protiva Biotherapeutics, Inc. Non-liposomal systems for nucleic acid delivery
US20120225129A1 (en) 2010-08-20 2012-09-06 Cerulean Pharma Inc. Conjugates, particles, compositions, and related methods
WO2012046265A1 (ja) * 2010-10-05 2012-04-12 トヨタ自動車株式会社 推定装置および推定方法
EP2500434A1 (en) 2011-03-12 2012-09-19 Association Institut de Myologie Capsid-free AAV vectors, compositions, and methods for vector production and gene delivery
CA2853689C (en) 2011-11-04 2020-06-30 Nitto Denko Corporation Method of producing lipid nanoparticles for drug delivery
WO2013073480A1 (ja) * 2011-11-18 2013-05-23 日油株式会社 細胞内動態を改善したカチオン性脂質
US9035039B2 (en) * 2011-12-22 2015-05-19 Protiva Biotherapeutics, Inc. Compositions and methods for silencing SMAD4
TWI595885B (zh) 2012-05-02 2017-08-21 喜納製藥公司 包含四galnac之新穎結合物及傳送寡核苷酸之方法
US10426737B2 (en) 2013-12-19 2019-10-01 Novartis Ag Lipids and lipid compositions for the delivery of active agents
CA2953341C (en) 2014-06-25 2023-01-24 Acuitas Therapeutics Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
HUE067372T2 (hu) 2015-06-29 2024-10-28 Acuitas Therapeutics Inc Lipidek és nanoszemcsés lipid formulázások nukleinsavak beadására
CN108368028B (zh) 2015-10-28 2021-09-03 爱康泰生治疗公司 用于递送核酸的新型脂质和脂质纳米颗粒制剂
WO2017084987A1 (en) 2015-11-16 2017-05-26 F. Hoffmann-La Roche Ag GalNAc CLUSTER PHOSPHORAMIDITE
DK3386484T3 (da) 2015-12-10 2022-07-04 Modernatx Inc Sammensætninger og fremgangsmåder til afgivelse af terapeutiske midler
US12678515B2 (en) 2015-12-30 2026-07-14 Acuitas Therapeutics, Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
IL261524B2 (en) 2016-03-03 2023-10-01 Univ Massachusetts End-capped linear double-stranded DNA for non-viral gene transfer
JP2019151589A (ja) * 2018-03-02 2019-09-12 国立大学法人北海道大学 脂質ナノ粒子
CA3094057C (en) * 2018-03-27 2025-04-08 Nof Corporation CATIONIC LIPID WITH IMPROVED INTRACELLULAR DYNAMICS
JP7075256B2 (ja) * 2018-03-28 2022-05-25 三菱重工業株式会社 配管の余寿命評価方法
CN114929205B (zh) 2019-09-06 2024-09-03 世代生物公司 包括末端封闭式dna和可切割脂质的脂质纳米颗粒组合物及其使用方法
US12534435B2 (en) 2020-03-27 2026-01-27 Generation Bio Co. Lipids and nanoparticle compositions thereof
AU2021307952A1 (en) * 2020-07-17 2023-03-02 Generation Bio Co. Methods for encapsulating polynucleotides into reduced sizes of Lipid nanoparticles and novel formulation thereof

Also Published As

Publication number Publication date
IL296763A (en) 2022-11-01
EP4125821A2 (en) 2023-02-08
WO2021195529A3 (en) 2021-11-18
JP7746280B2 (ja) 2025-09-30
WO2021195529A2 (en) 2021-09-30
KR20220160647A (ko) 2022-12-06
JP2025181861A (ja) 2025-12-11
JP2023518985A (ja) 2023-05-09
CN115916163A (zh) 2023-04-04
IL296763B1 (en) 2025-12-01
IL296763B2 (en) 2026-04-01
MX2022011988A (es) 2023-01-04
US20250361208A1 (en) 2025-11-27
US20240294474A1 (en) 2024-09-05
CA3173126A1 (en) 2021-09-30
EP4125821A4 (en) 2024-06-26
AU2021241696B2 (en) 2026-08-06
US12252470B2 (en) 2025-03-18
US12534435B2 (en) 2026-01-27
AU2021241696A1 (en) 2022-12-01
US20230159459A1 (en) 2023-05-25

Similar Documents

Publication Publication Date Title
BR112022007481A2 (pt) Lipídios ionizáveis e composições de nanopartículas dos mesmos
BR112023021504A2 (pt) Lipídios catiônicos e composições dos mesmos
MX2022011988A (es) Nuevos lipidos y composiciones de nanopartículas de estos.
MX2023014855A (es) Lípidos catiónicos y composiciones de estos.
MX2022014484A (es) Lipidos nuevos y composiciones de nanoparticulas de estos.
MX2022006948A (es) Composiciones y metodos para programar celulas terapeuticas utilizando nanoportadores de acidos nucleicos dirigidos.
BR112022004936A2 (pt) Compostos lipídicos contendo carbonato e composições para distribuição intracelular de agentes terapêuticos
BR112021021313A2 (pt) Lipídios de amina ionizáveis e nanopartículas de lipídio
BR112021025528A2 (pt) Derivados de sulfonamida de benzisoxazol
BR112022004771A2 (pt) Compostos e composições de lipídio de grupo de cabeça para entrega intracelular de agentes terapêuticos
BR112022001067A2 (pt) Inibidores duplos de atm e dna-pk para uso em terapia antitumoral
UY38382A (es) Agentes de arni para inhibir la expresión de 17beta-hsd tipo 13 (hsd17b13), composiciones de dichos agentes, y métodos de uso
EA202191313A1 (ru) Композиции на основе липидных наночастиц
BR112022004424A2 (pt) Pró-fármacos antivirais e formulações dos mesmos
BR0214386A (pt) Método para identificação de enzimas de objetivação a tumor
SG10201407996PA (en) Lipids, lipid compositions, and methods of using them
BRPI0515646A8 (pt) Proteína de fusão e formulação farmacêutica
CY1118281T1 (el) Γελες με βαση υαλουρονικο οξυ οι οποιες συμπεριλαμβανουν υδροχλωρικη λιδοκαϊνη
CY1118321T1 (el) Συστημα διαλυτων για βελτιωση της διαλυτοτητας των φαρμακευτικων παραγοντων
BR112014018990A8 (pt) Derivados de ácido benzotiazol-6-il acético e seu uso para tratamento de uma infecção
BR112023002951A2 (pt) Compostos de fosfolipídio e usos destes
BR112022019241A2 (pt) Agentes de rnai para inibição da expressão de pnpla3, composições farmacêuticas dos mesmos e métodos de uso
BR112013026345A2 (pt) composto, composição farmacêutica, uso de um composto, e, método para tratar um paciente infectado com hcv
An et al. Nonviral gene therapy in vivo with PAM-RG4/apoptin as a potential brain tumor therapeutic
CA3189073A1 (en) Lipid conjugates for the delivery of therapeutic agents

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]